pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›NINTEDANIB
drug · small molecule
save

nintedanib

Phase 3updated 6mo ago
by Cloudbreak Therapeutics LLC🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval10 co-mentions · 5 sources
  • tagSmall Molecule5 co-mentions · 5 sources
  • drugOfev5 co-mentions · 5 sources
  • drugNINTEDANIB ESYLATE5 co-mentions · 5 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 33 investigational indications.

indications

indications
Pulmonary Fibrosis

targets

Platelet-derived growth factor receptorVascular endothelial growth factor receptorFibroblast growth factor receptor

all catalysts(0)

nothing on the calendar yet

Trials studying nintedanib

  • phase2Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosisrecruitingn=210
  • —Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japancompletedn=586
  • phase1A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosiscompletedn=27
  • —Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patientsterminatedn=88
  • phase1A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participantsrecruitingn=57
  • phase1Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjectsrecruitingn=20
  • —Real-life-persistence to Antifibrotic Treatmentscompletedn=10,646
  • phase2Phase II Study of Docetaxel +/- Nintedanib in Breast Cancercompletedn=51

News(5)

  • Bristol Myers dips on ‘confounding’ lung drug results
    Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
    biopharma_dive · 1mo ago
  • Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
    Endeavor BioMedicines solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing to…
    fiercebiotech · 1mo ago
  • BMS reports liver injury events in lung disease program, with key readout near
    Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…
    biospace · 1mo ago
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    biopharma_dive · 4mo ago
  • Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
    The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
    biopharma_dive · 6mo ago
brand
NINTEDANIB
trade names
Nintedanib component of ofev, Ofev, Vargatef
generic
nintedanib
MOA
Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor
indication
Pterygium
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?